About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker NTRA · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 5, 2026Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532 · Breast Neoplasms, Carcinoma, Ductal, Breast
ctDNA-Guided Treatment Strategy
NTRA
Natera, Inc.
Not applicableRecruiting725May 15, 2032Registry ↗
Oct 27, 2026A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of C…
NCT07689812 · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-sma…
Signatera Genome ultra-sensitive ctDNA blood test
NTRA
Natera, Inc.
Not applicableNot yet recruiting920Aug 2034Registry ↗
Aug 17, 2026Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnan…
NCT05004337 · Vanishing Twin, Trisomy 21
NTRA
Natera, Inc.
—Completed136Nov 29, 2023Registry ↗
Aug 13, 2026Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder C…
NCT07763197 · Non-Muscle Invasive Bladder Cancer, NMIBC
NTRA
Natera, Inc.
—Recruiting400Jul 2032Registry ↗
Aug 6, 2026Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-N…
NCT07750886 · Non-Hodgkin Lymphoma, T-Cell Lymphoma
NTRA
Natera, Inc.
—Recruiting200Apr 2032Registry ↗
Jul 22, 2026Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT)
NCT07718633 · Kidney Transplant, Immunosuppresion
Prospera Immunosuppression Optimization
NTRA
Natera, Inc.
Not applicableNot yet recruiting750Dec 2027Registry ↗
Jun 17, 2026Signatera Assessment in Early-Stage Endometrial Cancer
NCT07339384 · Endometrial Cancer
Signatera Genome ultra-sensitive ctDNA blood test
NTRA
Natera, Inc.
Not applicableNot yet recruiting1,010Oct 2034Registry ↗
May 4, 2026Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esoph…
NCT07565857 · Gastric-Esophageal Cancer
Signatera Genome ultra-sensitive ctDNA blood test
NTRA
Natera, Inc.
Not applicableNot yet recruiting1,000Sep 2028Registry ↗
May 4, 2026EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
NCT06808880 · Single Gene NIPT
Single-gene Noninvasive Prenatal Testing (sgNIPT)
NTRA
Natera, Inc.
—Recruiting4,000Apr 2027Registry ↗
Feb 27, 2026A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-…
NCT06414603 · Heart Transplant Failure and Rejection
The Prospera™ Test
NTRA
Natera, Inc.
Not applicableActive, not recruiting250Feb 2027Registry ↗
Jan 15, 2026Sample Collection for Ongoing Research and Product Evaluation Study
NCT07318051 · Breast Cancer, Lung Cancer
NTRA
Natera, Inc.
—Recruiting9,600Jan 2035Registry ↗
Dec 12, 2025Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC)
NCT07046585 · Colo-rectal Cancer
NTRA
Natera, Inc.
—Recruiting25,000Jul 10, 2027Registry ↗
May 22, 2025Prospera Test Evaluation in Cardiac Transplant (ProTECT)
NCT05205551 · Heart Transplant Rejection
NTRA
Natera, Inc.
—Active, not recruiting411Oct 31, 2026Registry ↗
May 22, 2025LAMBDA 002 (Lung Registry) Study
NCT05170425 · Lung Transplant Rejection
Prospera
NTRA
Natera, Inc.
—Active, not recruiting154Aug 2026Registry ↗
Mar 18, 2025Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection
NCT03984747 · Transplant Rejection, Allograft Rejection
NTRA
Natera, Inc.
—Completed110Aug 23, 2024Registry ↗
Jan 29, 2025Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Can…
NCT06620627 · Colorectal Cancer Screening
NTRA
Natera, Inc.
—Recruiting5,000Jul 31, 2025Registry ↗
Oct 29, 2024Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation
NCT05309382 · Heart Transplant
Prospera
NTRA
Natera, Inc.
—Completed147Oct 2, 2024Registry ↗
Sep 26, 2024Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Manag…
NCT05312814 · Twin to Twin Transfusion Syndrome, Pregnancy Complications
NTRA
Natera, Inc.
—Completed137May 15, 2023Registry ↗
Aug 15, 2024BESPOKE Study of ctDNA Guided Immunotherapy
NCT04761783 · Colorectal Cancer, Melanoma
NTRA
Natera, Inc.
—Completed290Dec 31, 2023Registry ↗
Aug 6, 2024The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
NCT04091984 · Kidney Transplant Rejection
Prospera
NTRA
Natera, Inc.
—Active, not recruiting5,000Oct 1, 2026Registry ↗
Apr 3, 2024Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation
NCT05081739 · Heart Transplant Failure and Rejection
Prospera Transplant Assessment, Endomyocardial biopsy
NTRA
Natera, Inc.
Not applicableWithdrawn0Jan 2025Registry ↗
Dec 12, 2023BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
NCT04264702 · Colorectal Cancer, Colon Cancer
NTRA
Natera, Inc.
—Unknown1,788Sep 2025Registry ↗
Sep 28, 2023Renasight Clinical Application, Review and Evaluation (RenaCARE) Study
NCT05846113 · Kidney Diseases
Renasight
NTRA
Natera, Inc.
Not applicableUnknown1,720Aug 2025Registry ↗
Mar 23, 2023Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial
NCT01545674 · Trisomy 13, Trisomy 18
Blood Draw
NTRA
Natera, Inc.
—Terminated937Apr 2014Registry ↗
Jan 29, 2021SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
NCT02381457 · 22q11 Deletion Syndrome, DiGeorge Syndrome
NTRA
Natera, Inc.
—Completed20,960Jun 2020Registry ↗
Dec 30, 2020Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated…
NCT01852708 · Trisomy 21, Trisomy 18
NTRA
Natera, Inc.
—Completed1,059Oct 2020Registry ↗
Feb 6, 2020Natera Ovarian Cancer Detection Assay
NCT03485651 · Adnexal Mass
NTRA
Natera, Inc.
—Terminated12Nov 1, 2019Registry ↗
Aug 26, 2019Multiple Gestation Study
NCT02278536 · Trisomy 13, Trisomy 18
NTRA
Natera, Inc.
—Completed354Mar 2019Registry ↗
Aug 26, 2019Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Ce…
NCT02109770 · Microdeletion Syndromes, Trisomy 21
NTRA
Natera, Inc.
—Completed216Jun 2019Registry ↗
Jun 13, 2019High Risk Multiple Gestation Study
NCT02278874 · Trisomy 13, Trisomy 18
NTRA
Natera, Inc.
—Completed99Dec 1, 2018Registry ↗

30 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:28 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances